Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page
- Check6 days agoChange Detected- Revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 was added, and the prior funding-status notice and Revision: v3.4.1 note were removed.SummaryDifference0.5%

- Check41 days agoChange DetectedAdded a government funding/status notice regarding the NIH Clinical Center. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check48 days agoChange DetectedUI updates include adding a 'Show glossary' option, introducing a new label 'Last Update Submitted that Met QC Criteria,' updating the revision to v3.4.0, and capitalization tweaks for 'No FEAR Act Data'. These changes do not affect study content, eligibility criteria, or results.SummaryDifference0.2%

- Check56 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded a Locations section listing Florida. Updated the page revision to v3.3.3; the Florida Locations label and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.